Biohaven Ltd. (BHVN) Price & Analysis

Compare

814 Followers

BHVN Stock Chart & Stats

$9.45

-$0.59(-1.49%)

At close: Jan 08 4:00 PM EST

$9.45

-$0.59(-1.49%)

Day’s Range― - ―

52-Week Range$7.48 - $47.75

Previous CloseN/A

Volume146.24K

Average Volume (3M)4.61M

Market Cap

$875.42M

Enterprise Value$1.64B

Total Cash (Recent Filing)$260.22M

Total Debt (Recent Filing)$314.18M

Price to Earnings (P/E)―

Beta1.75

Next Earnings

Mar 19, 2026

EPS Estimate

-1.37

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.64

Shares Outstanding105,855,156

10 Day Avg. Volume9,159,106

30 Day Avg. Volume4,611,964

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)8.05

Price to Sales (P/S)0.00

P/FCF Ratio-5.81

Enterprise Value/Market Cap1.88

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.49K

Enterprise Value/Ebitda-2.08

Forecast

1Y Price Target

$18.50

Price Target Upside95.77% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering12

EPS Forecast (FY)-7.09

Revenue Forecast (FY)$266.67K

Bulls Say, Bears Say

Bulls Say

Phase 2 Data AnticipationThe next catalyst for Biohaven's stock is the anticipated Phase 2 data for Opakalim in major depressive disorder.

Pipeline And Program FocusBiohaven's prioritized pipeline now consists of the Kv7, degrader, and myostatin programs, with depression data expected and Phase III epilepsy data being significant milestones.

Strategic Cost OptimizationBiohaven is focusing on strategic portfolio and cost optimization, aiming to reduce annual direct R&D expenses by about 60%.

Bears Say

FDA Complete Response LetterBHVN received a Complete Response Letter from the FDA for its NDA for Troriluzole in spinocerebellar ataxia.

Regulatory ChallengesThe FDA expressed concerns about the proposal to conduct the natural history comparative analysis after the Phase III trial failed to meet primary and secondary endpoints.

Stock DowngradeBiohaven's stock rating was downgraded to Neutral due to an unclear catalyst path and limited visibility on the cash runway.

Biohaven Ltd. News

Biohaven call volume above normal and directionally bullish

Bullish option flow detected in Biohaven (BHVN) with 1,855 calls trading, 1.3x expected, and implied vol increasing over...

2d ago

BHVN

Biohaven price target lowered to $26 from $54 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Biohaven (BHVN) to $26 from $54 and keeps an Overweight...

2d ago

BHVN

Biohaven price target lowered to $14 from $28 at Citi

Citi lowered the firm’s price target on Biohaven (BHVN) to $14 from $28 and keeps a Buy rating...

7d ago

BHVN

Biohaven 23.33M share Spot Secondary priced at $7.50

J.P. Morgan, Goldman Sachs & Co., Leerink Partners, TD Cowen and Cantor are acting as book-running managers of...

8d ago

BHVN

Closing Bell Movers: AMD up 5% after unveiling medium term targets

In the opening hour of the evening session, U.S. equity futures are up marginally, with S&P 500 e-minis...

8d ago

ALC

Biohaven $150M Spot Secondary; price range $7.50-$8.00

JPMorgan and Goldman Sachs are acting as joint book running managers for the offering. Published first on TheFly...

9d ago

BHVN

Biohaven announces $150M common share offering

Biohaven (BHVN) Ltd. announced that it has commenced an underwritten public offering of $150M of its common shares....

9d ago

BHVN

Biohaven reports Q3 EPS ($1.64), consensus ($1.61)

Vlad Coric, chairman and CEO of Biohaven (BHVN), commented, “Biohaven remains energized and focused on our mission to...

10d ago

BHVN

Biohaven price target lowered to $30 from $75 at Piper Sandler

Piper Sandler lowered the firm’s price target on Biohaven (BHVN) to $30 from $75 and keeps an Overweight...

14d ago

BHVN

Biohaven price target lowered to $16 from $33 at BTIG

BTIG lowered the firm’s price target on Biohaven (BHVN) to $16 from $33 and keeps a Buy rating...

14d ago

BHVN

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Earnings reports, analyst updates, AI deals, and more are among the top stock market stories for Wednesday. ...

15d ago

AMD

BAC

Why Is Biohaven Stock (BHVN) Down 40% Today?

Biohaven stock fell hard on Wednesday alongside a response letter from the FDA. ...

15d ago

BHVN

Strategic Adjustments and Future Potential: Biohaven Ltd. Receives Buy Rating Amidst Regulatory Challenges

Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on Biohaven Ltd.. The associated price target...

2d ago

BHVN

Strategic Positioning and Growth Potential Drive Buy Rating for Biohaven Ltd.

Analyst Thomas Shrader from BTIG maintained a Buy rating on Biohaven Ltd. and keeping the price target at...

2d ago

BHVN

BHVN FAQ

What was Biohaven Ltd.’s price range in the past 12 months?

Biohaven Ltd. lowest stock price was $7.48 and its highest was $47.75 in the past 12 months.

What is Biohaven Ltd.’s market cap?

Biohaven Ltd.’s market cap is $875.42M.

When is Biohaven Ltd.’s upcoming earnings report date?

Biohaven Ltd.’s upcoming earnings report date is Mar 19, 2026 which is in 119 days.

How were Biohaven Ltd.’s earnings last quarter?

Biohaven Ltd. released its earnings results on Nov 10, 2025. The company reported -$1.64 earnings per share for the quarter, beating the consensus estimate of -$1.901 by $0.261.

Is Biohaven Ltd. overvalued?

According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Biohaven Ltd. pay dividends?

Biohaven Ltd. does not currently pay dividends.

What is Biohaven Ltd.’s EPS estimate?

Biohaven Ltd.’s EPS estimate is -1.37.

How many shares outstanding does Biohaven Ltd. have?

Biohaven Ltd. has 105,855,156 shares outstanding.

What happened to Biohaven Ltd.’s price movement after its last earnings report?

Biohaven Ltd. reported an EPS of -$1.64 in its last earnings report, beating expectations of -$1.901. Following the earnings report the stock price went down -5.69%.

Which hedge fund is a major shareholder of Biohaven Ltd.?

Currently, no hedge funds are holding shares in BHVN

Biohaven Ltd. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-522.08%

Trailing 12-Months

Asset Growth

-19.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Biohaven Ltd.

Biohaven Ltd. (BHVN) is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for neurological and neuropsychiatric diseases. The company operates in the healthcare sector and specializes in addressing unmet medical needs within the central nervous system (CNS) disorders. Biohaven's core products include FDA-approved treatments for migraine and other CNS conditions, leveraging its proprietary platforms and extensive research capabilities.

Biohaven Ltd. (BHVN) Earnings & Revenues

Historic Earnings Reports

BHVN Stock 12 Month Forecast

Average Price Target

$18.50

▲(95.77% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","51":"$51","18.75":"$18.75","29.5":"$29.5","40.25":"$40.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,18.75,29.5,40.25,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.2,18.184615384615384,19.16923076923077,20.153846153846153,21.138461538461538,22.123076923076923,23.107692307692307,24.092307692307692,25.076923076923077,26.06153846153846,27.046153846153846,28.03076923076923,29.015384615384615,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.2,17.3,17.4,17.5,17.599999999999998,17.7,17.8,17.9,18,18.1,18.2,18.3,18.4,{"y":18.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.2,16.569230769230767,15.938461538461539,15.307692307692307,14.676923076923076,14.046153846153846,13.415384615384614,12.784615384615384,12.153846153846153,11.523076923076923,10.892307692307693,10.26153846153846,9.63076923076923,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":50.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.74,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.18,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >